RAPT(Delisted)
RAPT Therapeutics·NASDAQ
--
--(--)
5.49 / 10
Netural
Analyst coverage is neutral, with all six analysts issuing Neutral ratings; historical weighted rating is 2.95, slightly below market expectations. Fund flow analysis, however, is excellent (8.03/10). Small, Medium, and Large order flows show positive trends, while block and extra-large flows are negative, indicating institutional caution but retail and mid-size participation. The overall fund flow pattern suggests liquidity support for the stock's upward trend, complementing the bullish technicals and strong fundamentals.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
0%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Emily BodnarNeutral
Date2026-01-20
InstitutionHC Wainwright & Co.
Times predicted4
Historical Win Rate75.0%
Etzer DaroutNeutral
Kaveri PohlmanNeutral
Thomas SmithNeutral
Yanan ZhuNeutral
What is the market sentiment for RAPT?
- RAPT holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.49/10 (Netural).
